Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer

Anti-Cancer Drugs

Volumn 10, Issue 8, 1999, Pages 693-698

  Gwyther, Stephen J ^a   Aapro, Matti S ^a,b   Hatty, Sarah R ^c   Postmus, Pieter E ^d   Smith, Ian E ^e  

^a EAST SURREY HOSPITAL   (United Kingdom)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c Sarah Hatty Associates   (United Kingdom)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Gemcitabine; Independent review; Non small cell lung cancer; Response rates

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE;

ADULT; AGED; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW;

EID: 0033386066     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199909000-00001     Document Type: Review

References (24)

1. 1. Zelen M. Guidelines for publishing papers on cancer clinical trials: responsibilities of editors and authors. J Clin Oncol 1983; 1: 164-9.
2. 2. Simon R, Wittes RE. Methodologic guidelines for reports of clinical trials. Cancer Treat Rep 1985; 69: 1-3.
3. R (docetaxel) as a new treatment in breast cancer. Breast Cancer Res Treat 1995; 33: 39-46.
4. 4. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 1996; 14: 422-8.
5. 5. Gwyther S, Bolis G, Gore M, et al. Experience with independent radiological review during a topotecan trial in ovarian cancer. Ann Oncol 1997; 8: 463-8.
6. 6. Notice for guidance on evaluation of anticancer medicinal products in man. CPMP/EWP/205/95; adopted December 1996.
7. 7. Food and Drug Administration. New drug, antibiotics and biological drug product regulations: accelerated approval final rule. Federal Register 11 December 1992; 57: 58942-60.
8. 8. Anderson H, Lund F, Bach N, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1821-6.
9. 9. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1535-40.
10. 10. Lund B, Ryberg LM, Meidahl-Petersen P, Anderson H, Thatcher N, Dombernowsky P. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol 1994; 5: 852-3.
11. 11. Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicenter, extended phase II study. Eur J Cancer 1996; 32A: 243-8.
12. 12. FDA Proposals for Reform. Reinventing the regulation of cancer drugs. March 1996.
13. 13. WHO handbook for reporting results of cancer treatment. Geneva: WHO 1979.
14. 14. Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976; 38: 388-94.
15. 15. Lavin PT, Flowerdew G. Studies in variation associated with the measurement of solid tumors. Cancer 1980; 46: 1286-90.
16. 16. Warr D, McKinney S, Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol 1984; 2: 1040-6.
17. 17. Herschorn S, Hanley JA, Wolkove N, et al. Measurability of non-small-cell lung cancer on chest radiographs. J Clin Oncol 1986; 4: 1184-90.
18. 18. Gurland J, Johnson RO. How reliable are tumor measurements? J Am Med Ass 1965; 194: 125-30.
19. 19. Hopper KD, Kasales CJ, Van Slyke MA, Schwartz TA, TenHave TR, Jozefiak JA. Analysis of interobserver and intraobserver variability in CT tumor measurements. Am J Roentgenol 1996; 167: 851-4.
20. 20. Eli Lilly and Co. Data on file.
21. 21. Quoix E, Wolkove N, Hanley J, Kreisman H. Problems in radiographic estimation of response to chemotherapy and radiotherapy in small cell lung cancer. Cancer 1988; 62: 489-93.
22. 22. Grossman SA, Burch PA. Quantitation of tumor response to antineoplastic therapy. Semin Oncol 1988; 15: 441-54.
23. 23. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
24. 24. Davis HL, Multhauf P, Klotz J. Comparisons of cooperative group evaluation criteria for multiple-drug therapy for breast cancer. Cancer Treat Rep 1980; 64: 507-17.